Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.

ABSTRACT:

SUBMITTER: Subbiah V 

PROVIDER: S-EPMC8119360 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature